Parkinson's Disease, Idiopathic Clinical Trial
Official title:
PDx Biomarker Assay Study for the Diagnosis of Parkinson's Disease
The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients. Differential diagnosis includes patients with Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia, Essential Tremor and Normal Controls.
In this study, the PDx assay will be designed and validated in order to distinguish between
Idiopathic Parkinson's disease (PD) to patients with similar symptoms and healthy controls.
The differential diagnosis cohort includes patients diagnosed with Multiple System Atrophy
(MSA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Essential
Tremor (ET) or Lewy Body Dementia (LBD) and Healthy Controls.
This is a prospective observational study. Blood samples and clinical data will be collected
at the first and only study visit. The expression levels of 5 to 6 genes will be analyzed by
blinding technicians concerning the diagnosis, demographic data and clinical data, which will
be revealed after sending PDx gene expression values to the clinical sites. The gene
expression levels will be compared between Parkinson's disease patients to the differential
diagnosis cohort and healthy controls. Additional mRNA and miRNA markers will be explored.
The primary aim of the study is to design and validate a clinical classifier that will aid
the physician in the diagnosis of Parkinson's disease patients. The analysis will be
performed in two stages: Stage 1) Exploration analysis and Stage 2) Validation. After one
year of taking a blood sample, the study physician will contacted to confirm the patient's
diagnosis.
Blood samples will be collected at specialized movement disorder clinics.
Medical history, clinical diagnostic features, family history in regard to Parkinson's
disease, use of medication and routine imaging assessment (not mandatory) will be collected
at the first and only patient visit.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00507715 -
Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk
|
Phase 1 | |
| Recruiting |
NCT02879136 -
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease
|
Early Phase 1 | |
| Completed |
NCT05357989 -
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
|
Phase 3 | |
| Completed |
NCT05575479 -
PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables
|